The Lung Disease Bet That's Banking on a $4 Billion Market Nobody's Cracked

The pipeline has three candidates, each at a different stage:

AP01 is inhaled pirfenidone, currently in a Phase 2b trial called MIST for progressive pulmonary fibrosis. Earlier Phase 1b data (from a study called ATLAS) showed patients on the 100 mg twice-daily dose had near-stabilization of lung function over 48 weeks, with good tolerability. Full Phase 2b data should arrive by the end of 2027.

AP02 is inhaled nintedanib, which has completed Phase 1 testing in both healthy volunteers and IPF patients. A Phase 2 trial called AURA is underway, with the first patient dosed in March 2026.

AP03 is the ambitious one: a fixed-dose combination of both pirfenidone and nintedanib in a single inhaled treatment. It's still in preclinical work, but it tackles a real problem. Doctors know combining the two oral drugs could help more patients, but the stacked side effects make it impractical. An inhaled combo could change that math entirely.

Show Me the Money

Avalyn isn't exactly scraping by. The company entered 2026 with $138 million in cash, having raised over $300 million across venture rounds. That includes a $100 million Series D closed in July 2025. Investors include names like RiverVest, FPrime Capital, and Catalio Capital. The team is lean: just 51 employees, with 32 in R&D.

CEO Lyn Baranowski brings a track record that venture investors love. She previously served as COO at Altavant Sciences and was VP of Commercial Development at Pearl Therapeutics, which AstraZeneca bought for $1.15 billion. IPO proceeds would primarily fund the Phase 2b/3 program for AP01, the Phase 2/3 path for AP02, and early human testing for AP03.

A Crowded Waiting Room

Avalyn isn't the only company eyeing better IPF treatments. Bristol Myers Squibb, AbbVie, and United Therapeutics all have programs in the space, though the graveyard of failed IPF trials is long and sobering. Boehringer Ingelheim's BI 1015550 is another one to watch.

Leerink Partners analyst Faisal Khurshid described the recent IPF approval Jascayd as a "modest advance," underscoring just how high the bar remains. The financial rewards for cracking this disease, though, are enormous. Esbriet and Ofev became multi-billion-dollar franchises despite their tolerability headaches. An inhaled version that works as well (or better) with fewer side effects could capture significant share, especially since inhaled therapies are the fastest-growing segment in the IPF market, expanding at a 9.85% annual clip.

Timing the IPO Window

Avalyn is filing into what looks like a genuinely open IPO window for biotech. After a brutal 2025, early 2026 has been markedly different. At least six U.S. biotechs have priced offerings totaling roughly $1.77 billion, with some supersized deals: Generate:Biomedicines raised $400 million, Eikon Therapeutics pulled in $381 million, and Aktis Oncology upsized to $318 million.

Analysts are cautiously bullish on the trend. Michael Rachlin of FTI Consulting called 2026 a "more discerning IPO marketplace" that favors companies with "proven, later-stage assets." Ben Folwell at Evaluate projected 40 to 60 biotechs could go public this year if M&A momentum holds. A baseline estimate of 30 to 35 IPOs seems reasonable.

Avalyn fits the profile investors want right now: clinical-stage data, a clear path to Phase 3, and a reformulation strategy for drugs with proven biology. Over two-thirds of biotech IPOs since 2022 have involved Phase 2 or later programs, and Avalyn checks that box.

The Bottom Line

Avalyn's thesis is elegant in its simplicity. Don't invent a new molecule; just deliver proven ones more intelligently. If the clinical data holds up, inhaled versions of pirfenidone and nintedanib could meaningfully improve life for patients who currently have to choose between slowing their disease and tolerating brutal side effects.

The risk, of course, is that reformulation stories don't always pan out. Phase 2b and Phase 3 trials are where good ideas go to get stress-tested against reality. And the IPF space has humbled plenty of well-funded companies before.

But with $138 million in the bank, a top-tier investor syndicate, and an IPO market that's finally breathing again (pun very much intended), Avalyn has positioned itself for a real shot. We'll be watching for pricing details in the coming weeks.

Neurocrine Just Bet $2.9 Billion on a Disease Most People Have Never Heard Of

Neurocrine Biosciences is spending $2.9 billion to acquire the only approved drug for a rare hunger disorder most people have never heard of. The deal says a lot about where biotech's biggest bets are heading.